To Meet Demand, Forma Aims To Boost Discovery Supply
This article was originally published in Start Up
Forma Therapeutics has already convinced several big industry partners its discovery engine will yield oncology candidates in emerging areas of research. Now it wants to find academic groups to help feed its engine, all while the resurgent biotech IPO market might make its unusual structure superfluous.
You may also be interested in...
With Celgene Deal, Forma Makes First Foray Into Clinical Development
Forma Therapeutics has signed its largest and most ambitious oncology drug-discovery and development collaboration to date, in the exciting but early-stage area of protein homeostasis. Its new partner Celgene is no stranger to making big bets on promising cancer companies.
New $80 Million U.K. Asset-Centric Cancer Research Fund Set Up With EU, Charity Funding
The U.K.'s Cancer Research Technology and the European Investment Fund join forces to launch an asset-centric investment fund to bridge the development gap, the third new U.K. fund in two weeks.
Genentech Licenses A Cancer Metabolism Program From Forma, With Option To Buy
The Roche-owned biotech licensed a novel oncology target from the startup, but could take outright possession of the program - with a payout for VCs.